@NaokiNiikura Profile picture

Naoki Niikura

@NaokiNiikura

Professor Tokai University, Department of breast surgery, Clinical and Translational researcher, I love a family, triathlon ,travel, Yoga

Joined December 2009
Similar User
tatsunori_shimoi photo

@shimoi_oncology

BC Tube 編集部|乳腺・乳がんに関する医療情報発信 photo

@bc_tube

Yukinori Ozaki photo

@YukinoriOzaki

KONISHI Takaaki@外科 photo

@konishita_sur

高橋將人(北海道大学病院乳腺外科教授) photo

@Masato_Nyusen

東北大学病院腫瘍内科 photo

@TUH_DMO

高野 利実 Toshimi Takano photo

@ToshimiHBM

海外がん医療情報リファレンス photo

@cancer_ref

Kazuki Nozawa, MD photo

@kazuki_nozawa

日本がん対策新聞@かんぱち編集長 photo

@gantaisaku1105

Shu Yazaki, MD, PhD photo

@ShuYazaki

日本臨床腫瘍学会(JSMO) photo

@JSMO_official

Mitsuo Terada, MD, PhD@乳腺科医 photo

@MamMa_mimumemo

一般社団法人日本癌学会 photo

@jcaopl

リオールジム / 女性向けメディカルジム photo

@koki_fitness

1つの選択肢、natureにアクセプト、この意味は大きい

The results of SONIA are out on @Nature 1L use of palbo did not improve PFS over 2L use, but led to more AEs & costs. An evolving treatment landscape challenges its interpretation— yet it shows that sequencing trials are possible. Congrats to the authors! nature.com/articles/s4158…

Tweet Image 1


Naoki Niikura Reposted

T-DXd Demonstrates Efficacy in HER2+ Metastatic Breast Cancer With Stable or Active Brain Metastases @nlinmd @DanaFarber #bcsm #oncology onclive.com/view/t-dxd-dem…


TROPION-BREAST01 DaTO-DXd vs Chemo for HR+\HER2- PFS延長もOS延長を示すことができず。

Press release: despite improving PFS vs chemo, Dato-DXd did not meet the dual primary endpoint of OS for HR+/HER2- MBC in the TROPION-Breast01 trial. Full data at #SABCS24? astrazeneca.com/media-centre/p…

Tweet Image 1


KN-522 update OS Chemo + Pembro prolong OS HR 0.66 5y OS 88.6%

Tweet Image 1
Tweet Image 2
Tweet Image 3

Impressive!!

📌 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) in the neoadjuvant setting: Results from the I-SPY 2.2 trial @MeghnaTrivedi3 #ESMO24 @OncoAlert #OncoAlertAF • Highest pCR rate observed in Immune+ (79%) followed by TNBC (62%) subtypes • > 50%…

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4


Naoki Niikura Reposted

#ESMO24 | DESTINYBreast-12: arrivano gli attesi risultati di T-DXd nel #carcinomamammario metastatico con o senza metastasi cerebrali. Il commento a caldo di @BianchiniGP 👇🏼 Non perdere l’intervista completa a breve su Oncoinfo! 🔜 @myESMO


DB-12の結果はNature medicineに同時発表されています。

🔥Hot off the Press! Trastuzumab deruxtecan in HER2-positive advanced #BreastCancer with or without #BrainMetastases practice changing results from a phase 3b/4 trial. 🔓nature.com/articles/s4159… #ESMO24 @NatureMedicine @nlinmd @Prof_Nadia_H @evaciruelos @volkmar_mueller

Tweet Image 1


CAPItello-290 capivasertive +PTX 1st line TNBC No difference PFS and OS #ESMO2024

Tweet Image 1
Tweet Image 2

HER3-Dxd HR+\HER2- ORR 53.5% mPFS 9.4 m HER2 0 40% patients

Tweet Image 1
Tweet Image 2
Tweet Image 3

DB-12 T-DXd for with or without Brain metastasis. 12month mCNS-PFS 58.9% Active BM 60.1% Stable BM 57.8% No different mCNS-PFS active and stable BM

Tweet Image 1
Tweet Image 2

Naoki Niikura Reposted

📌 Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases 🧠: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM) | Breast Cancer link.springer.com/article/10.100…

Tweet Image 1
Tweet Image 2

Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM) was published from BC link.springer.com/article/10.100…


Continuing medical education (CME)の日本版を担当します。 1年前のESMO2023の内容になり,日本語訳もついています HR+Adj、ADCの1時間のディスカッション(日本語でOK)を行います。 医師、看護師、薬剤師などの医療関係者は参加可能です。定員は15名の先着順ですscientificseminars.gathered.com/invitation?ref…


Naoki Niikura Reposted

《朗報》 2日の第二部会にてフリュザクラ(大腸がん)、タフィスゴ(FGFR2融合遺伝子陽性胆道がん)、アレセンサ(ALK融合遺伝子陽性肺がんの術後補助療法)の承認が了承され、キイトルーダの非小細胞肺がんにおける術前・術後補助療法の承認が報告された。 gantaisaku.net/yakuji_240802/


脳転移/髄膜がん腫症を伴うHER2+乳がんへのT-DXd、長期の有効性を評価(ROSET-BM)/日本乳癌学会 Carenet医療ニュース #carenet carenet.com/news/general/c…


日本人でのPhase1大丈夫かな? chugai-pharm.co.jp/news/detail/20…


CIPNの発症率は、対照群で70.6%であったのに対し、SMT群では30.0%、WBVトレーニング群では41.2%であり、対照群に比べて介入群で減少 タキサン系でも同じ結果になるか? 運動が化学療法による末梢神経障害の回避に有効か Carenet医療ニュース #carenet carenet.com/news/general/h…


医師の方しか見れませんがこんな活動もしています upstream.surgery

Tweet Image 1

Naoki Niikura Reposted

Phase 1 trial of the HER2 topo1 ADC SHR-A1811 out in @JCO_ASCO Impressive activity among pts with HER2+ (ORR 76%, left) and HER2-low (ORR 60%, right) MBC, & in multiple other tumor types. ILD: 2.6%, 13 deaths due to AEs (4.2%), 4 treatment-related (1.3%). ascopubs.org/doi/10.1200/JC…

Tweet Image 1

インパクトファクター503.1とか一生かかっても獲得できない数字、インフレが止まらないですね

The 2023 Impact Factor for CA: A Cancer Journal for Clinicians is 503.1. CA is proud to continue its commitment to publishing free-to-access, high-quality content aligned with the @AmericanCancer mission to end cancer as we know it, for everyone.

Tweet Image 1


Loading...

Something went wrong.


Something went wrong.